Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ONO-2808 in Healthy Subjects
NCT04578028Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-2808 in multiple system atrophy (MSA) (8 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Treatment emergent adverse events at Day 17 and Serious adverse events at Day 17. Started Aug 2020; status: completed.
02
Drugs
ONO-2808
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04578028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578028.